Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemotherapy in Locally Advanced UTUC
NCT04672317Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in upper urinary tract urothelial carcinoma (UTUC), sponsored by Renji Hospital. Primary endpoint: Pathological complete response rate. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
upper urinary tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT04672317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672317.